Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaebok Choi

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Plos One|July 22, 2015
GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow TransplantationAmy M Becker, Derrick J Callahan, Justin M Richner, et al.
Blood|April 29, 2010
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemiaJaebok Choi, Julie Ritchey, Julie L Prior, et al.
Blood|September 14, 2012
IFNγR signaling mediates alloreactive T-cell trafficking and GVHDJaebok Choi, Edward D Ziga, Julie Ritchey, et al.
Cell Stress & Chaperones|March 20, 2024
HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cellsChristopher Butler, Morgan Dunmire, Jaebok Choi, et al.
The Journal of Clinical Investigation|November 3, 2021
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantationStephen P Persaud, Julie K Ritchey, Sena Kim, et al.
Science Signaling|March 21, 2023
The adrenal stress response is an essential host response against therapy-induced lethal immune activationLing Guo, Weinan Wang, Qian Wang, et al.
Blood|December 8, 2022
S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in miceSena Kim, Sora Lim, Boram Kim, et al.
Transplantation and Cellular Therapy|February 22, 2023
A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell TransplantationArmin Rashidi, Eric J Huselton, Heather E Stefanski, et al.
Leukemia|July 25, 2021
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFRSena Kim, Kidist Ashami, Sora Lim, et al.
Frontiers in Immunology|September 25, 2023
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant modelsRamzi Abboud, Sena Kim, Karl Staser, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Plos One|July 22, 2015
GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow TransplantationAmy M Becker, Derrick J Callahan, Justin M Richner, et al.
Blood|April 29, 2010
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemiaJaebok Choi, Julie Ritchey, Julie L Prior, et al.
Blood|September 14, 2012
IFNγR signaling mediates alloreactive T-cell trafficking and GVHDJaebok Choi, Edward D Ziga, Julie Ritchey, et al.
Cell Stress & Chaperones|March 20, 2024
HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cellsChristopher Butler, Morgan Dunmire, Jaebok Choi, et al.
The Journal of Clinical Investigation|November 3, 2021
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantationStephen P Persaud, Julie K Ritchey, Sena Kim, et al.
Science Signaling|March 21, 2023
The adrenal stress response is an essential host response against therapy-induced lethal immune activationLing Guo, Weinan Wang, Qian Wang, et al.
Blood|December 8, 2022
S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in miceSena Kim, Sora Lim, Boram Kim, et al.
Transplantation and Cellular Therapy|February 22, 2023
A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell TransplantationArmin Rashidi, Eric J Huselton, Heather E Stefanski, et al.
Leukemia|July 25, 2021
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFRSena Kim, Kidist Ashami, Sora Lim, et al.
Frontiers in Immunology|September 25, 2023
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant modelsRamzi Abboud, Sena Kim, Karl Staser, et al.
Pageof 4